Dassault Systèmes Completes Acquisition of Medidata

Article

Dassault Systèmes has announced the completion of its acquisition of Medidata Solutions, which will connect the 3DEXPERIENCE platform with a clinical trial platform and opens up virtual twin experiences for healthcare.

In an Oct. 29, 2019 press release, Dassault Systèmes has announced the completion of its acquisition of Medidata Solutions, which will connect the 3DEXPERIENCE platform with a clinical trial platform and opens up virtual twin experiences for healthcare.

“Together with Medidata’s solutions and its great talents that we are delighted to welcome, we bring an unmatched combination of assets to reinforce our vision, science-based culture, and life sciences industry knowledge and know-how. Medidata will be a core brand in our information intelligence domain,” said Bernard Charlès, vice-chairman and CEO, Dassault Systèmes, in the press release. “By combining data intelligence and simulation, we power smarter therapeutics for healthier people. The inclusive and multi-discipline 3DEXPERIENCE platform will be key for healthcare innovators to anticipate and address the needs of the industry’s transformation toward affordable precision healthcare in the 21st century. The virtual world will push the bounds of possibilities to transform not only research and science, but also the entire pharmaceutical and medical device industry and medicine, in general.” 

“The Medidata and Dassault Systèmes teams already share a common vision to build sustainable innovation and improve lives, and now we will move forward with our shared commitment to a full integration that will benefit our clients and partners,” added Tarek Sherif, co-founder, chairman, and CEO, Medidata, in the press release. “With the combination of Dassault Systèmes and Medidata, we have never been in a stronger position to fulfill our ambition to bring the right treatment to the right patient at the right time.”

Source: Dassault Systèmes

 

Recent Videos
Behind the Headlines, episode 7
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content